Takuya Sato1, Noriko Gotoh. 1. The University of Tokyo, Institute of Medical Science, Division of Systems Biomedical Technology, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. ngotoh@ims.u-tokyo.ac.jp
Abstract
BACKGROUND: There are two members--FRS2alpha and FRS2beta--in the fibroblast growth factor receptor substrate 2 (FRS2) family of docking/scaffolding adaptor proteins. These proteins function downstream of certain kinds of receptor tyrosine kinases (RTKs) that are important for tumorigenesis. FRS2alpha acts as a control centre for fibroblast growth factor receptor signalling and encourages tumorigenesis, while FRS2beta regulates EGFR signalling negatively, and might have a tumour suppressive role. Therefore, both proteins could be good therapeutic targets for the treatment of cancer. OBJECTIVE: To examine the physiological and pathological roles of FRS2, especially in cancer, and describe their potential value as therapeutic targets. METHODS: A review of relevant literature. RESULTS/ CONCLUSIONS: Although it is still difficult to develop small compounds to modify functions of FRS2 adaptor proteins, such compounds may be useful as the next generation of molecular targeting drugs. Combination therapy with RTK-targeting drugs and FRS2-targeting drugs may be useful for cancer treatment in the near future.
BACKGROUND: There are two members--FRS2alpha and FRS2beta--in the fibroblast growth factor receptor substrate 2 (FRS2) family of docking/scaffolding adaptor proteins. These proteins function downstream of certain kinds of receptor tyrosine kinases (RTKs) that are important for tumorigenesis. FRS2alpha acts as a control centre for fibroblast growth factor receptor signalling and encourages tumorigenesis, while FRS2beta regulates EGFR signalling negatively, and might have a tumour suppressive role. Therefore, both proteins could be good therapeutic targets for the treatment of cancer. OBJECTIVE: To examine the physiological and pathological roles of FRS2, especially in cancer, and describe their potential value as therapeutic targets. METHODS: A review of relevant literature. RESULTS/ CONCLUSIONS: Although it is still difficult to develop small compounds to modify functions of FRS2 adaptor proteins, such compounds may be useful as the next generation of molecular targeting drugs. Combination therapy with RTK-targeting drugs and FRS2-targeting drugs may be useful for cancer treatment in the near future.
Authors: Lei Zhang; Hua Xiao; Hui Zhou; Silverio Santiago; Jay M Lee; Edward B Garon; Jieping Yang; Ole Brinkmann; Xinmin Yan; David Akin; David Chia; David Elashoff; No-Hee Park; David T W Wong Journal: Cell Mol Life Sci Date: 2012-06-12 Impact factor: 9.261
Authors: Barbara Barylko; Yu-Ju Chen; Jared Hennen; Isaac Angert; Yan Chen; Joachim D Mueller; Hui-Qiao Sun; Clinton A Taylor; Jen Liou; Helen Yin; Joseph P Albanesi Journal: Biochemistry Date: 2019-06-11 Impact factor: 3.162
Authors: Isaac Angert; Siddarth Reddy Karuka; Jared Hennen; Yan Chen; Joseph P Albanesi; Louis M Mansky; Joachim D Mueller Journal: Biophys J Date: 2019-12-12 Impact factor: 4.033
Authors: Zhi Sheng; Li Li; Lihua J Zhu; Thomas W Smith; Andrea Demers; Alonzo H Ross; Richard P Moser; Michael R Green Journal: Nat Med Date: 2010-05-23 Impact factor: 53.440
Authors: Pei-Yu Chen; Lingfeng Qin; Zhen W Zhuang; George Tellides; Irit Lax; Joseph Schlessinger; Michael Simons Journal: Proc Natl Acad Sci U S A Date: 2014-04-02 Impact factor: 11.205
Authors: Swadesh K Das; Santanu Maji; Stephen L Wechman; Praveen Bhoopathi; Anjan K Pradhan; Sarmistha Talukdar; Devanand Sarkar; Joseph Landry; Chunqing Guo; Xiang-Yang Wang; Webster K Cavenee; Luni Emdad; Paul B Fisher Journal: Pharmacol Res Date: 2020-02-13 Impact factor: 7.658